Emil Frei

American physician and oncologist

Emil "Tom" Frei III (February 21, 1924 – April 30, 2013) was an American physician and oncologist. He was the former director and former physician in chief of the Dana–Farber Cancer Institute in Boston, Massachusetts. He was also the Richard and Susan Smith Distinguished Professor of Medicine at Harvard Medical School.

Frei was born in 1924 in St. Louis. His family owned the stained glass manufacturer Emil Frei & Associates. Frei completed an accelerated pre med Colgate University in 1944 after only 2 years of study and his medical degree from Yale University in 1948.

He interned at Firmin Desloge Hospital, now St. Louis University Hospital in St. Louis, Missouri and served as a physician in the Korean War. He worked at the National Cancer Institute from 1955 to 1965 and the M. D. Anderson Cancer Center from 1965 to 1972; while at M. D. Anderson he was the founding director of the Department of Development Therapeutics, which evolved into the Clinical Research Center. He served as physician in chief at the Dana Farber Institute from 1972 to 1991. He is best known for his work on the treatment of lymphomas and childhood and adult leukemia. His groundbreaking research into then controversial combination chemotherapy, including the VAMP regimen, earned him many awards. He coauthored "Cancer Medicine" with Dr. James F. Holland.

Frei was one of the founders of the Acute Leukemia Group B which later evolved into the Cancer and Leukemia Group B (CALGB). He served as the group chair for 16 years, from 1956 to 1963, and again from 1981 to 1990.

He coined the Journal of Clinical Oncology in 1981, journal published first issue in 1983 in association with American Society of Clinical Oncology.

Frei died of Parkinson's disease at his home in Oak Park, Illinois on April 30, 2013. He was 89.